| Combination of | |
|---|---|
| Bupivacaine | Local anesthetic |
| Meloxicam | Nonsteroidal anti-inflammatory drug (NSAID) |
| Clinical data | |
| Trade names | Zynrelef |
| Other names | HTX-011 |
| License data |
|
| Routes of administration | Intralesional, infiltration |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Bupivacaine/meloxicam, sold under the brand name Zynrelef, is a fixed-dose combination medication used to treat pain in small to medium-sized wounds after surgery.[1][2][4] It contains bupivacaine and meloxicam.[1][2]
The most common side effects of bupivacaine/meloxicam are dizziness, constipation, vomiting, and headache.[1][2]
It was approved for medical use in the European Union in September 2020,[2] and in the United States in May 2021.[1][5]
YouTube Encyclopedic
-
1/5Views:43 4521 69310 1981 86030 825
-
Methylprednisolone preferred for treatment of lower back pain in patients with facet joint syndrome
-
5.14.2020 Urology COViD Didactics - Acute and Chronic Scrotal Content Pain
-
Pain Control: Opioids, Non-Opioids and Local Anesthetics | Advanced EM Pharmacology Workshop
-
Anaesthesia for Laparoscopic surgery, Acute Postop pain management
-
Midazaolam Injection Uses,Mechanism Of Action,Contraindications & Side Effects In Hindi / Mezolam
Transcription
Medical uses
In the European Union, the combination bupivacaine/meloxicam is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults.[2]
In the United States it is indicated for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty in adults.[1][5]
References
- ^ a b c d e f "Zynrelef- bupivacaine and meloxicam solution". DailyMed. Retrieved 8 January 2022.
- ^ a b c d e f "Zynrelef EPAR". European Medicines Agency (EMA). 22 July 2020. Retrieved 6 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Zynrelef Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ Blair HA (July 2021). "Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain". Drugs. 81 (10): 1203–1211. doi:10.1007/s40265-021-01551-9. PMID 34228280. S2CID 235744803.
- ^ a b "Heron Therapeutics Announces U.S. FDA Approval of Zynrelef (HTX-011) for the Management of Postoperative Pain for up to 72 Hours" (Press release). Heron Therapeutics. 13 May 2021. Retrieved 14 May 2021 – via PR Newswire.
External links
- "Bupivacaine mixture with meloxicam". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT03295721 for "Bunionectomy Study for Postoperative Analgesia (EPOCH 1)" at ClinicalTrials.gov
- Clinical trial number NCT03237481 for "Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)" at ClinicalTrials.gov
- Clinical trial number NCT03015532 for "Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia" at ClinicalTrials.gov
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams |
|
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 24 May 2023, at 13:03